Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

Daxor Corporation

DXR
7,18
0,0498 (0,70%)
14 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/2/202514:00GLOBEDaxor's Blood Volume Analysis Uncovers Hidden Heart Failure..
13/2/202514:00GLOBENew Multicenter Study Highlights Utility of Daxor’s Blood..
22/1/202515:17EDGAR2Form NPORT-P - Monthly Portfolio Investments Report on Form..
18/12/202414:00GLOBEDaxor Expands Its BVA-100™ Blood Volume Diagnostic to Two..
11/12/202400:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202400:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202400:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/10/202414:00GLOBEDAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED..
08/10/202414:00GLOBEDaxor Corporation to Participate in a Fireside Chat at the..
27/9/202423:00GLOBEDaxor Corporation Streamlines Regulatory Strategy for..
19/9/202414:00GLOBEDaxor Corporation to Exhibit at the Heart Failure Society of..
12/9/202414:00GLOBENewly Published Review Highlights the Pivotal Role of..
05/9/202414:00GLOBEDaxor Corporation Receives $300K Matching Fund Award From..
04/9/202414:30GLOBELeading Central Florida Hospital Implements Daxor’s BVA-100™..
03/9/202422:05GLOBEDaxor Corporation CEO and President Michael Feldschuh..
03/9/202418:15GLOBEDaxor Corporation to Present at the H.C. Wainwright 26th..
29/8/202423:16EDGAR2Form N-CSRS - Certified Shareholder Report, Semi-Annual
29/8/202414:00GLOBEDaxor Corporation Announces Launch of BVA Program at..
23/8/202422:52EDGAR2Form 40-17G - Fidelity Bond [Rule 17G-1(g)]
16/8/202423:23EDGAR2Form N-2 - Registration statement for closed-end investment..
06/8/202414:00GLOBEDaxor Corporation Awarded $1.9M Contract by The U.S. Air..
05/8/202414:00GLOBEDaxor Expands To Three New Facilities As Blood Volume..
24/7/202414:00GLOBEDaxor Corporation Awarded New U.S. Defense Health Agency..
18/7/202420:46EDGAR2Form 8-K - Current report
18/7/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202423:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202423:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/7/202414:00GLOBEDaxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands..
18/6/202414:00GLOBEDaxor Corporation to Showcase the Benefits of BVA-100™..
05/6/202422:10EDGAR2Form 8-K - Current report
05/6/202414:00GLOBEDaxor Corporation Appoints John L. Jefferies, M.D. as Chief..
16/4/202414:00GLOBENew Studies Prove the Clinical Benefits of Daxor’s Blood..
15/4/202414:00GLOBEDAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR..
10/4/202414:00GLOBEDaxor Corporation Announces New Hospital Account at Leading..
01/4/202414:00GLOBEDaxor Corporation to Exhibit at the American College of..
25/3/202413:00GLOBEDaxor Corporation Acquires Volumex® and Megatope® From Its..
22/3/202413:00GLOBEDaxor Corporation to Hold Investor Call Discussing Fiscal..
18/3/202419:18GLOBEDaxor Corporation CEO and President Michael Feldschuh..
11/3/202413:00GLOBEDaxor Announces Sales to Three New Hospitals Furthering..
08/3/202419:49EDGAR2Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of..
08/3/202414:00GLOBEMulti-Center Study Presented by Duke at Heart Failure..
06/3/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202423:28EDGAR2Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of..
29/2/202422:15EDGAR2Form NT-NCSR - Notice under Exchange Act Rule 12b-25 of..
26/2/202414:00GLOBEDaxor Corporation to Exhibit at the Technology and Heart..
Apertura: 7,17 Min: 7,06 Max: 7,2499
Chiusura: 7,1302

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network